CUDC-907: Additional Phase I data

Data from 10 evaluable patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) in an open-label, dose-escalation, U.S. Phase I trial showed that CUDC-907 led to 2 complete responses...